Opzelura Shows Strong Results in Phase 3b Trial for Moderate Atopic Dermatitis
New data support European filing for nonsteroidal topical treatment.
Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical signs and symptoms, including itch relief as early as day 2.
The trial met its co-primary endpoints at week 8, with:
- 70% of patients treated with Opzelura achieving a ≥75% improvement in Eczema Area and Severity Index (EASI75)
- 61.3% reaching Investigator’s Global Assessment Treatment Success (IGA-TS)
“The TRuE-AD4 data further reinforce the safety and efficacy profile of Opzelura and its ability to control key signs and symptoms of moderate AD, including improvement in bothersome symptoms like itch.” - Jim Lee, Group Vice President, Inflammation & Autoimmunity at Incyte
Author's summary: Opzelura shows strong results in phase 3b trial for moderate atopic dermatitis.
More News
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- GRID Powers Up: XSite Braehead Unveils Bold New Identity
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- The Future of Communication in Latin America and the Caribbean: How Faxing Software Is Transforming Business Operations | Sounds and Colours
- The State Of Startups In 7 Charts: These Sectors And Stages Are Down As AI Megarounds Dominate In 2025
- 'Slaysian Royale' international queens perform at Shady Brunch
- Drewrys land and two adjacent sites draw no bids for South Bend Redevelopment Commission
- Crane arrival marks major milestone for $526.8m Ryde Hospital Redevelopment
- Andy Cohen Praises a Dallas Church for its Reponse to Gov. Abbott's War on Crosswalks